Clinical Gene Therapy: ASGCT Indo-UK Symposium

October 9, 2021 | 2 - 7 p.m. IST


In collaboration with the CureSMA Foundation of India, Hemophilia Society Lucknow Chapter, Hemophilia Society Mumbai Chapter, the Indian Society of Clinical Research, KJ Somaiya Ayurvihar Hospital and Research Center, and Organization for Rare Diseases India.

During this free virtual symposium, attendees will gain insights on how to successfully initiate trials of in vivo and ex vivo gene therapies in India.

Agenda

Download the PDF

Session I 

2:00 –2:10 PM: Introduction 
Kenneth Cornetta, MD, Indiana University

Gene Therapy for Monogenic Diseases

2:10 – 2:35 PM: Development of Indigenous Gene Therapy Technologies: Progress and Prospects
Jayandharan G. Rao, PhD, IIT-Kanpur

2:35 – 3:00 PM: Gene Therapy for Hemophilia B
Edward Tuddenham, MD, University College London

3:00 – 3:15 PM: Discussion

Break 
3:15—3:30 PM 

Session II     

CAR T-Cell Therapy: Opportunities and Challenges

3:30 – 3:55 PM: Guidelines on Stem Cell Therapy in India
Geeta Jotwani, PhD, Indian Council for Medical Research

3:55 – 4:20 PM: CAR T-Cell Therapy: Indian Scenario
Vikram Mathews, MD, Christian Medical College, Vellore

4:20 – 4:45 PM: CAR T-Cells for Treatment of Acute Lymphoblastic Leukemia
Persis Amrolia, Great Ormond Street Hospital

4:45 – 5:00 PM: Discussion

Break 
5:00 – 5:15 PM

Session III     

Emerging Therapies in Lower Middle-Income Countries

5:15 – 5:40 PM: Current Challenges in the Development of Gene Therapies: Industry Perspective
Federico Mingozzi, PhD, Spark Therapeutics

5:40 - 6:05 PM: Emerging Therapies in India: Where are we?
Savita Rangarajan, MD, Southampton General Hospital & KJ Somaiya Hospital, Mumbai

6:05 - 6:30 PM: Emerging Therapies in India: Government Priorities and the way Forward
Vinod K. Paul, MD, PhD, Member, NITI Aayog, Government of India

6:30-6:45 PM: Discussion  

6:45—7 PM: Closing remarks 

Thank You to Our Sponsor:

 

2025

Class Considerations on Immunogenicity for AAV GT Products

January 22-23, 2025 | Virtual

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.